Tacrolimus (Topical)
Tacrolimus Topical — Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Moderate-to-severe atopic dermatitis | Adults ≥16 years (0.03% or 0.1%) | Second-line monotherapy | FDA Approved |
| Moderate-to-severe atopic dermatitis | Children 2–15 years (0.03% only) | Second-line monotherapy | FDA Approved |
Tacrolimus topical is FDA-approved exclusively for moderate-to-severe atopic dermatitis in non-immunocompromised patients who have failed to respond adequately to other topical prescription therapies or when those treatments are not advisable. It is designated as second-line therapy, meaning topical corticosteroids should generally be tried first. The 0.1% strength provides additional efficacy over 0.03% in adults, particularly those with severe disease, extensive body surface area involvement, or in Black patients. In children aged 2–15 years, only the 0.03% concentration is approved, and there was insufficient evidence that 0.1% offered additional benefit over 0.03% in this population (FDA PI).
Vitiligo (facial/non-segmental): Tacrolimus 0.1% ointment applied twice daily has demonstrated repigmentation in multiple studies, particularly for facial lesions. A multicenter RCT confirmed superiority over vehicle at 24 weeks for facial vitiligo. Best results on face/neck; limited efficacy on extremities and trunk. Evidence quality: Moderate (RCTs, consensus statements from Pigmentary Disorders Society).
Inverse / facial psoriasis: Effective for psoriasis affecting thin-skin areas (face, genitals, intertriginous folds) where topical steroids carry high atrophy risk. Multiple open-label studies show clearance in 71–81% of patients. Evidence quality: Moderate (open-label studies, one RCT).
Oral lichen planus: Used as 0.1% ointment applied directly to oral mucosal lesions. Systematic reviews support efficacy in reducing pain and erosion area. Evidence quality: Moderate (systematic review and meta-analysis).
Seborrheic dermatitis, lichen sclerosus, cutaneous lupus: Smaller evidence base; used when topical steroids are contraindicated or have caused adverse effects. Evidence quality: Low to Moderate.
Dosing
Dosing by Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Moderate-to-severe AD — adults ≥16 years, initial treatment | 0.03% or 0.1% ointment BID | Thin layer to affected areas BID | 0.1% BID | Apply to affected areas only; stop when signs/symptoms resolve 0.1% preferred for severe disease, extensive BSA, or Black patients (greater efficacy shown in pivotal trials) |
| Moderate-to-severe AD — children 2–15 years | 0.03% ointment BID | Thin layer to affected areas BID | 0.03% BID | Only 0.03% is approved for this age group; 0.1% not recommended Not indicated for children <2 years (FDA boxed warning) |
| AD — facial and intertriginous involvement (adults) | 0.03% or 0.1% ointment BID | Thin layer BID | 0.1% BID | Preferred over topical corticosteroids on face/eyelids/neck to avoid steroid-induced atrophy No skin atrophy risk unlike topical steroids; can be used on face long-term with intermittent dosing |
| AD — proactive maintenance (flare prevention) | 0.03% or 0.1% ointment twice weekly | Apply to previously affected areas 2 days/week | 0.1% twice weekly | Apply to sites commonly affected even when clear (proactive approach) Review after 12 months; supported by EMA-approved indication in Europe but off-label in USA |
| AD — steroid-sparing switch (adults/children) | Age-appropriate strength BID | Thin layer BID | Age-appropriate max | Initiated when topical corticosteroids cause local adverse effects (atrophy, striae, telangiectasia) or are inadequate No taper required from previous topical steroid; can start tacrolimus immediately |
Application-site burning affects up to 58% of patients in early treatment and is the most common reason for non-adherence. To reduce burning: (1) apply to fully dry skin after bathing, (2) pre-cool the ointment in the refrigerator for 15–20 minutes before application, (3) apply an emollient 15–20 minutes before tacrolimus, (4) warn patients that burning typically resolves within the first week as the skin barrier improves. With the 0.1% formulation, 90% of burning events lasted between 2 minutes and 3 hours with a median duration of 15 minutes (FDA PI).
Pharmacology
Mechanism of Action
Tacrolimus is a macrolide immunosuppressant isolated from Streptomyces tsukubaensis. It exerts its immunomodulatory effect by binding to the intracellular protein FKBP-12 (FK506-binding protein 12). The resulting tacrolimus–FKBP-12 complex then binds calcium, calmodulin, and calcineurin, inhibiting the phosphatase activity of calcineurin. This prevents dephosphorylation and nuclear translocation of the nuclear factor of activated T-cells (NF-AT), a transcription factor essential for the expression of pro-inflammatory cytokines including IL-2, IL-3, IL-4, IL-5, GM-CSF, TNF-α, and IFN-γ. The net effect is suppression of T-lymphocyte activation and downstream inflammatory cascades. Unlike topical corticosteroids, tacrolimus does not cause skin atrophy because it does not affect fibroblast collagen synthesis or suppress the hypothalamic–pituitary–adrenal axis. Additionally, tacrolimus inhibits the release of preformed mediators from mast cells and basophils and downregulates FcεRI expression on Langerhans cells, which may contribute to its antipruritic and anti-inflammatory effects in atopic dermatitis.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Topical bioavailability ~0.5%; peak blood levels <2 ng/mL in 85% of adult patients and 98% of pediatric patients; systemic exposure ~30-fold lower than oral immunosuppressive doses | Systemic immunosuppression is not expected at topical doses; absorption declines as the epidermal barrier heals with treatment, providing a built-in safety margin |
| Distribution | ~99% protein-bound (albumin, α1-acid glycoprotein); high erythrocyte association (whole blood:plasma ratio ~35); not metabolised in skin | The drug remains concentrated locally in the skin; high protein binding limits the free fraction available for systemic effects |
| Metabolism | Hepatic via CYP3A4; major metabolite is 13-demethyl tacrolimus (similar activity to parent); demethylation and hydroxylation are primary pathways | CYP3A4 inhibitors could theoretically increase systemic tacrolimus levels, though this is only clinically relevant with extensive application on compromised skin barriers |
| Elimination | Predominantly faecal (>92%); urinary ~2.3%; <1% unchanged in urine; elimination t½ ~43–48 h (based on IV/oral data) | Long systemic half-life is clinically irrelevant for topical use at standard doses given the minimal absorption; no accumulation observed with intermittent topical use for up to 1 year (FDA PI) |
Side Effects
Adverse effect data are from the three pivotal phase 3, vehicle-controlled, 12-week trials (983 patients total: 351 pediatric, 632 adult) and open-label safety studies involving over 9,000 additional patients, as reported in the FDA prescribing information for Protopic.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Application-site burning / stinging | Up to 58% | Most common adverse event; typically occurs within minutes of application and resolves within the first week of treatment as skin barrier heals. Median duration 15 min (0.1%); 90% resolve within 3 hours (FDA PI) |
| Pruritus (application site) | Up to 46% | Paradoxical early worsening of itch before improvement; median duration 20 min; 90% of events resolve within 10 hours. Decreases over time with continued treatment |
| Erythema (application site) | Up to 28% | Transient redness at treated site; usually accompanies burning; distinguishable from flare by temporal pattern (occurs within minutes, resolves within hours) |
| Skin infection (any type) | Up to 16% | Includes bacterial, viral, and fungal infections; patients with AD have baseline predisposition to skin infections; monitor for secondary impetiginisation |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 1–10% | Usually mild and self-limiting; listed as common in pivotal trials; consider systemic absorption if persistent |
| Flu-like symptoms (rhinitis, pharyngitis) | 1–10% | Upper respiratory symptoms reported more frequently than with vehicle; likely reflects seasonal overlap rather than direct drug effect in most cases |
| Folliculitis | 1–10% | Inflamed hair follicles at application site; more common in hairy areas; usually self-resolving; listed as increased risk in EMA SmPC |
| Acne | 1–10% | Increased risk noted in EMA SmPC; more commonly reported in adolescent and adult populations; differentiate from steroid acne if switching from topical corticosteroid |
| Herpes simplex | 1–10% | Increased risk of HSV reactivation at or near treated areas; patients with history of recurrent herpes should be counselled; listed as increased risk in EMA SmPC |
| Alcohol-related facial flushing | 1–10% | Cutaneous vasodilation with facial warmth and redness after alcohol consumption; self-limiting; typically resolves within 20–30 minutes; listed in both FDA PI and EMA SmPC |
| Skin tingling / paraesthesia | 1–10% | Altered skin sensation at application site; commonly observed per EMA SmPC; may persist for several hours; mediated by neuropeptide release from sensory nerve fibres |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Lymphadenopathy | 0.8% (112/13,494) | Variable; usually infection-related | Investigate aetiology; most resolved with antibiotics. Discontinue if no clear cause or if EBV positive. Monitor until resolved |
| Eczema herpeticum (Kaposi varicelliform eruption) | 0.5% (24/4,400 pediatric) | Any time during treatment | Discontinue tacrolimus; start systemic antiviral (aciclovir/valaciclovir) immediately; dermatology/infectious disease referral |
| Malignancy (skin cancer, lymphoma) — theoretical risk | Very rare (causal link not established) | Post-marketing reports; long-term | Avoid continuous long-term use; limit UV exposure; perform routine skin examinations; FDA boxed warning in effect |
| Varicella zoster reactivation | <5% (children) | Any time during treatment | Evaluate risk-benefit; initiate antiviral if clinical shingles or primary varicella develops; consider temporary discontinuation |
| Acute renal failure | Very rare (post-marketing) | Reported in patients with barrier defects or extensive application | Avoid use in conditions with compromised skin barrier (Netherton syndrome, erythroderma); monitor renal function if extensive use on damaged skin |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Application-site burning | 1–3% | Most common drug-related reason; nearly always occurs in the first week; proper patient counselling about transient nature reduces discontinuation |
| Skin infection | <1% | Eczema herpeticum or bacterial superinfection requiring drug interruption; AD patients have baseline infection susceptibility |
| Lack of efficacy | Variable | Reassess diagnosis if no improvement within 6 weeks; some conditions (CTCL) can mimic AD |
Burning is the most clinically important side effect because it drives early discontinuation. Evidence-based strategies to reduce burning include: applying tacrolimus to completely dry skin (wait at least 20 minutes after bathing), storing the tube in the refrigerator before use, applying a moisturiser first as a buffer, and starting with the 0.03% concentration before stepping up to 0.1% if tolerated. Patients should be explicitly warned that burning typically peaks in the first 3–5 days and then subsides substantially as the atopic lesions begin to heal. This counselling alone significantly improves adherence.
Drug Interactions
No formal topical drug interaction studies have been conducted with tacrolimus ointment (FDA PI). Given minimal systemic absorption (~0.5% bioavailability), interactions with systemically administered drugs are unlikely under standard conditions. However, interactions become clinically relevant when tacrolimus ointment is applied to large body surface areas, compromised skin barriers, or in patients with erythrodermic disease where systemic absorption may increase. Tacrolimus is metabolised by CYP3A4.
Monitoring
-
Clinical Response
6-week review
Routine If no improvement within 6 weeks, re-examine the patient and confirm the diagnosis. Conditions such as cutaneous T-cell lymphoma (CTCL) can mimic atopic dermatitis and should be excluded before continued treatment (FDA PI). -
Skin Examination
Each visit
Routine Assess treated areas for signs of secondary infection (bacterial, viral, fungal). Check for new or changing skin lesions given the theoretical malignancy concern in the boxed warning. Note: unlike topical steroids, atrophy and striae are not expected. -
Lymph Nodes
Each visit
Routine Lymphadenopathy occurred in 0.8% of patients in clinical trials. If lymphadenopathy develops without clear infectious aetiology or in the presence of EBV mononucleosis, discontinue tacrolimus and investigate. Monitor until resolution. -
Viral Infections
As needed
Trigger-Based Monitor for signs of eczema herpeticum (vesicles, punched-out erosions, fever), herpes simplex reactivation, or varicella zoster. If suspected, discontinue tacrolimus and initiate antiviral therapy promptly. -
Sun Exposure
Ongoing
Routine Advise patients to minimise natural and artificial UV exposure during treatment. It is unknown whether tacrolimus ointment interferes with the skin's response to UV damage. Sunscreen and protective clothing should be used. -
Growth (Pediatric)
Regular intervals
Routine Though tacrolimus does not suppress the HPA axis, growth monitoring is advisable in children on any long-term topical treatment. No growth suppression has been reported with topical tacrolimus.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to tacrolimus or any excipient (mineral oil, paraffin, propylene carbonate, white petrolatum, white wax).
- Children under 2 years of age — safety and efficacy not established; use not recommended per FDA boxed warning.
Relative Contraindications (Specialist Input Recommended)
- Skin barrier defect conditions (Netherton syndrome, lamellar ichthyosis, generalised erythroderma, cutaneous graft-versus-host disease) — increased systemic absorption reported in post-marketing cases; elevated tacrolimus blood levels documented.
- Pre-malignant or malignant skin conditions — tacrolimus should not be applied to areas of known or suspected skin malignancy. Some malignancies (e.g., CTCL) may mimic atopic dermatitis.
- Immunocompromised patients — safety and efficacy have not been studied in this population; use is not recommended.
- Active cutaneous infections (bacterial, viral including herpes simplex/varicella, fungal) at proposed treatment sites — infections must be treated and resolved before initiating tacrolimus.
Use with Caution
- Concomitant CYP3A4 inhibitors with widespread skin application — theoretical risk of increased systemic exposure.
- Pregnancy — Category C; systemic tacrolimus crosses the placenta and is associated with neonatal hyperkalemia and renal dysfunction. Topical use has not been adequately studied; use only if benefit clearly outweighs risk.
- Lactation — systemic tacrolimus is excreted in human milk; it is unknown whether topical application results in detectable milk levels. Consider risk-benefit; avoid application to breasts if nursing.
- Extensive UV exposure — patients should minimise sun and tanning bed exposure; the drug's effect on UV-damage response is unknown.
Although a causal relationship has not been established, rare cases of malignancy (including skin cancer and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including tacrolimus ointment. Therefore: continuous long-term use should be avoided and application limited to areas of involvement with atopic dermatitis; tacrolimus ointment is not indicated for use in children under 2 years of age; only the 0.03% concentration is approved for children 2–15 years; and tacrolimus ointment should be used as second-line therapy for patients who have failed or cannot use other topical treatments. A Medication Guide must be dispensed with each prescription.
Patient Counselling
Purpose of Therapy
Tacrolimus ointment is used to treat moderate-to-severe eczema (atopic dermatitis) that has not responded well to other topical treatments. Unlike steroid creams, tacrolimus does not thin the skin, making it especially useful for sensitive areas like the face, eyelids, and neck. It works by calming the overactive immune response in the skin that causes redness, itching, and inflammation.
How to Apply
Make sure the skin is completely clean and dry before application — wait at least 20 minutes after bathing. Apply a thin layer of ointment to the affected areas only, twice a day. Rub it in gently. Wash your hands after applying (unless hands are the area being treated). Do not cover treated areas with bandages or wraps. You may use moisturisers after the ointment has been absorbed, but check with your prescriber about compatible products.
Sources
- PROTOPIC (tacrolimus) Ointment 0.03% and 0.1% — FDA Prescribing Information (2011 revision). Astellas Pharma US. accessdata.fda.gov Primary FDA label: contains pivotal trial efficacy data, full adverse event tables, pharmacokinetics, boxed warning text, and dosing information.
- PROTOPIC (tacrolimus) Ointment — FDA Prescribing Information (original 2000 label). accessdata.fda.gov Original FDA label at approval; includes detailed pharmacokinetic data and clinical trial results for the phase 3 studies.
- FDA Safety Communication: Tacrolimus (marketed as Protopic Ointment) Information. fda.gov FDA safety page detailing the 2006 boxed warning update, malignancy concern, second-line therapy designation, and age restrictions.
- Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol. 2007;157(5):861–873. doi:10.1111/j.1365-2133.2007.08177.x Comprehensive safety review of topical tacrolimus including long-term data from open-label studies; addresses malignancy concern and local adverse event patterns.
- Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44(1 Suppl):S58–S64. doi:10.1067/mjd.2001.109812 Pivotal pediatric safety data from the open-label extension study; confirms no increase in adverse events with prolonged use up to 1 year.
- Wollenberg A, Reitamo S, Atzori F, et al. Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008;63(7):742–750. doi:10.1111/j.1398-9995.2008.01683.x Key trial establishing the proactive twice-weekly maintenance regimen for preventing AD flares; forms the basis for EMA-approved maintenance indication.
- Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi:10.1016/j.jaad.2014.03.023 AAD guideline positioning topical calcineurin inhibitors as second-line therapy for atopic dermatitis; discusses steroid-sparing role and facial/eyelid use.
- Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi:10.1111/jdv.14891 European consensus guidelines; recommends tacrolimus for sensitive skin sites and proactive maintenance therapy in atopic dermatitis.
- Calcineurin Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. ncbi.nlm.nih.gov/books/NBK558995 NCBI reference covering the calcineurin inhibition pathway, FKBP-12 binding, topical tacrolimus formulations, and comparative pharmacology of calcineurin inhibitors.
- Kim JE, Bae M, Kim HS, et al. Incidence of topical tacrolimus adverse effects in chronic skin disease. Ann Dermatol. 2021;33(2):172–176. doi:10.5021/ad.2021.33.2.172 Retrospective study of adverse event incidence across different dermatologic conditions; reports lower AE rates in vitiligo versus atopic dermatitis and rosacea.
- Malecic N, Young H. Tacrolimus for the management of psoriasis: clinical utility and place in therapy. Psoriasis (Auckl). 2016;6:153–163. doi:10.2147/PTT.S101233 Review of topical and oral tacrolimus efficacy in psoriasis, particularly facial and inverse disease; summarises 22 clinical studies.
- Sarkar R, Dogra S, Vinay K, et al. Topical tacrolimus in vitiligo: consensus paper from the Pigmentary Disorders Society. Clin Cosmet Investig Dermatol. 2024;17:2875–2886. doi:10.2147/CCID.S490539 Expert consensus on tacrolimus use in vitiligo using modified Delphi methodology; recommends 0.1% BID for non-segmental facial vitiligo with best results on face/neck.
- Drugs and Lactation Database (LactMed). Tacrolimus. Bethesda (MD): NICHD; 2024. ncbi.nlm.nih.gov/books/NBK501922 LactMed summary of systemic tacrolimus during breastfeeding; notes that topical absorption is minimal but caution is advised given systemic excretion in milk.